Northern Trust’s VistaGen Therapeutics VTGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $41.5K | Hold |
72,655
| – | – | ﹤0.01% | 4269 |
|
|
2025
Q4 | $48.1K | Buy |
72,655
+24,562
| +51% | +$88.7K | ﹤0.01% | 4287 |
|
|
2025
Q3 | $171K | Hold |
48,093
| – | – | ﹤0.01% | 4025 |
|
|
2025
Q2 | $96.2K | Hold |
48,093
| – | – | ﹤0.01% | 4116 |
|
|
2025
Q1 | $120K | Buy |
48,093
+2,882
| +6% | +$8.16K | ﹤0.01% | 4072 |
|
|
2024
Q4 | $133K | Sell |
45,211
-4,220
| -9% | -$11.9K | ﹤0.01% | 4100 |
|
|
2024
Q3 | $149K | Sell |
49,431
-531
| -1% | -$1.81K | ﹤0.01% | 3965 |
|
|
2024
Q2 | $174K | Sell |
49,962
-56
| -0.1% | -$242 | ﹤0.01% | 3903 |
|
|
2024
Q1 | $264K | Buy |
50,018
+1,179
| +2% | +$5.67K | ﹤0.01% | 3792 |
|
|
2023
Q4 | $251K | Buy |
48,839
+34,315
| +236% | +$130K | ﹤0.01% | 3808 |
|
|
2023
Q3 | $76.1K | Buy |
14,524
+4,171
| +40% | +$18.5K | ﹤0.01% | 4069 |
|
|
2023
Q2 | $19.4K | Sell |
10,353
-51,024
| -83% | -$179K | ﹤0.01% | 4417 |
|
|
2023
Q1 | $230K | Buy |
61,377
+3,138
| +5% | +$16.5K | ﹤0.01% | 3801 |
|
|
2022
Q4 | $180K | Buy |
58,239
+8,221
| +16% | +$30.9K | ﹤0.01% | 3910 |
|
|
2022
Q3 | $228K | Sell |
50,018
-2,950
| -6% | -$29.2K | ﹤0.01% | 3824 |
|
|
2022
Q2 | $1.4M | Sell |
52,968
-1,532
| -3% | -$54.1K | ﹤0.01% | 3234 |
|
|
2022
Q1 | $2.03M | Sell |
54,500
-10,643
| -16% | -$464K | ﹤0.01% | 3096 |
|
|
2021
Q4 | $3.81M | Sell |
65,143
-1,438
| -2% | -$93.6K | ﹤0.01% | 2860 |
|
|
2021
Q3 | $5.47M | Sell |
66,581
-2,725
| -4% | -$237K | ﹤0.01% | 2672 |
|
|
2021
Q2 | $6.55M | Buy |
69,306
+60,541
| +691% | +$4.49M | ﹤0.01% | 2669 |
|
|
2021
Q1 | $560K | Buy |
8,765
+5,549
| +173% | +$370K | ﹤0.01% | 3781 |
|
|
2020
Q4 | $187K | Sell |
3,216
-310
| -9% | -$7.91K | ﹤0.01% | 3982 |
|
|
2020
Q3 | $74K | Buy |
3,526
+870
| +33% | +$18K | ﹤0.01% | 4034 |
|
|
2020
Q2 | $42K | Hold |
2,656
| – | – | ﹤0.01% | 4072 |
|
|
2020
Q1 | $35K | Buy |
2,656
+335
| +14% | +$6.13K | ﹤0.01% | 4010 |
|
|
2019
Q4 | $48K | Hold |
2,321
| – | – | ﹤0.01% | 4064 |
|
|
2019
Q3 | $75K | Hold |
2,321
| – | – | ﹤0.01% | 3984 |
|
|
2019
Q2 | $51K | Hold |
2,321
| – | – | ﹤0.01% | 4081 |
|
|
2019
Q1 | $89K | Hold |
2,321
| – | – | ﹤0.01% | 3944 |
|
|
2018
Q4 | $104K | Buy |
2,321
+1,457
| +169% | +$79.4K | ﹤0.01% | 3911 |
|
|
2018
Q3 | $38K | Hold |
864
| – | – | ﹤0.01% | 4165 |
|
|
2018
Q2 | $36K | Hold |
864
| – | – | ﹤0.01% | 4161 |
|
|
2018
Q1 | $24K | Buy |
864
+500
| +137% | +$18.6K | ﹤0.01% | 4155 |
|
|
2017
Q4 | $12K | Hold |
364
| – | – | ﹤0.01% | 4187 |
|
|
2017
Q3 | $17K | Hold |
364
| – | – | ﹤0.01% | 4172 |
|
|
2017
Q2 | $20K | Hold |
364
| – | – | ﹤0.01% | 4182 |
|
|
2017
Q1 | $21K | Buy |
+364
| New | +$29.5K | ﹤0.01% | 4150 |
|
Other funds holding VTGN
O
TCM
VCM
ACM
IC
Northern Trust's VTGN Position: Q1 2026 in Review
Northern Trust held its VistaGen Therapeutics (VTGN) position steady in Q1 2026 at 72,655 shares worth $41.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4269.
Northern Trust first reported a position in VTGN in Q1 2017 and has held it in 37 quarters since. The position peaked at $6.55M in Q2 2021. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.
- Northern Trust held 72,655 shares of VistaGen Therapeutics worth $41.5K as of Q1 2026.
- Northern Trust left its VistaGen Therapeutics share count unchanged in Q1 2026.
- VistaGen Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4269 holding.
- Northern Trust first reported a position in VistaGen Therapeutics in Q1 2017 and has held it in 37 quarters since.
- Northern Trust's VistaGen Therapeutics position peaked at $6.55M in Q2 2021.
- 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.